Dimerix Enrolls First Kidney Patient to Open Label Extension Study; Shares Fall 6%
Dimerix (ASX:DXB) enrolled the first patient to an open-label extension study for its kidney disease medication DMX-200, according to a Tuesday filing with the Australian bourse.
The patient completed the pharmaceutical firm's phase three trial investigating the use of DMX-200 to treat focal segmental glomerulosclerosis, a condition that may lead to kidney scarring, the filing added.
The patient will now continue their treatment for up to two years as part of the open-label study, the filing stated.
Dimerix's shares fell 6% in recent trade.
Price (AUD): $0.38, Change: $-0.025, Percent Change: -6.17%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。